{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:53:57Z","timestamp":1790906037920,"version":"4.1.0"},"reference-count":130,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"DOI":"10.1007\/s00198-026-08236-7","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:23:38Z","timestamp":1790843018000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Modern pharmacological management of Osteoporosis: from monotherapy to sequential and combination approaches in postmenopausal women"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6708-9105","authenticated-orcid":false,"given":"Valeria","family":"Rella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Rotondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Barile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonello","family":"Trotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Paolo","family":"Cantatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Addolorata","family":"Corrado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"8236_CR1","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.2147\/TCRM.S138000","volume":"14","author":"F Pouresmaeili","year":"2018","unstructured":"Pouresmaeili F, Kamalidehghan B, Kamarehei M, Goh YM (2018) A comprehensive overview on osteoporosis and its risk factors. Ther Clin Risk Manag 14:2029\u20132049. https:\/\/doi.org\/10.2147\/TCRM.S138000","journal-title":"Ther Clin Risk Manag"},{"key":"8236_CR2","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1186\/s13018-021-02772-0","volume":"16","author":"N Salari","year":"2021","unstructured":"Salari N, Ghasemi H, Mohammadi L et al (2021) The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis. J Orthop Surg Res 16:609. https:\/\/doi.org\/10.1186\/s13018-021-02772-0","journal-title":"J Orthop Surg Res"},{"issue":"10","key":"8236_CR3","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1007\/s00198-022-06454-3","volume":"33","author":"PL Xiao","year":"2022","unstructured":"Xiao PL, Cui AY, Hsu CJ et al (2022) Global, regional prevalence, and risk factors of osteoporosis according to the World Health Organization diagnostic criteria: a systematic review and meta-analysis. Osteoporos Int 33(10):2137\u20132153. https:\/\/doi.org\/10.1007\/s00198-022-06454-3","journal-title":"Osteoporos Int"},{"issue":"9","key":"8236_CR4","doi-asserted-by":"publisher","first-page":"e580","DOI":"10.1016\/S2666-7568(21)00172-0","volume":"2","author":"Global Burden Disease Fracture Collaborators","year":"2021","unstructured":"Global Burden Disease Fracture Collaborators (2021) Global, regional, and national burden of bone fractures in 204 countries and territories, 1990\u20132019: a systematic analysis from the global burden of disease study 2019. Lancet Healthy Longev 2(9):e580\u2013e592. https:\/\/doi.org\/10.1016\/S2666-7568(21)00172-0","journal-title":"Lancet Healthy Longev"},{"issue":"8","key":"8236_CR5","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s001980070064","volume":"11","author":"JA Kanis","year":"2000","unstructured":"Kanis JA, Johnell O, Oden A et al (2000) Long-term risk of osteoporotic fracture in Malm\u00f6. Osteoporos Int 11(8):669\u2013674. https:\/\/doi.org\/10.1007\/s001980070064","journal-title":"Osteoporos Int"},{"key":"8236_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/bmb\/ldaa005","volume":"133","author":"MA Clynes","year":"2020","unstructured":"Clynes MA, Harvey NC, Curtis EM, Fuggle NR, Dennison EM, Cooper C (2020) The epidemiology of osteoporosis. Br Med Bull 133:105\u2013117. https:\/\/doi.org\/10.1093\/bmb\/ldaa005","journal-title":"Br Med Bull"},{"issue":"12","key":"8236_CR7","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1097\/GME.0000000000001263","volume":"25","author":"JC Gallagher","year":"2018","unstructured":"Gallagher JC (2018) Advances in osteoporosis from 1970 to 2018. Menopause 25(12):1403\u20131417. https:\/\/doi.org\/10.1097\/GME.0000000000001263","journal-title":"Menopause"},{"issue":"10","key":"8236_CR8","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1093\/jbmr\/zjae119","volume":"39","author":"F Cosman","year":"2024","unstructured":"Cosman F, Lewiecki EM, Eastell R et al (2024) Goal-directed osteoporosis treatment: ASBMR\/BHOF task force position statement 2024. J Bone Min Res 39(10):1393\u20131405. https:\/\/doi.org\/10.1093\/jbmr\/zjae119","journal-title":"J Bone Min Res"},{"issue":"1","key":"8236_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-025-01588-3","volume":"20","author":"CL Gregson","year":"2025","unstructured":"Gregson CL, Armstrong DJ, Avgerinou C et al (2025) The 2024 UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 20(1):119. https:\/\/doi.org\/10.1007\/s11657-025-01588-3","journal-title":"Arch Osteoporos"},{"issue":"10","key":"8236_CR10","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1001\/jama.2025.6003","volume":"334","author":"SN Morin","year":"2025","unstructured":"Morin SN, Leslie WD, Schousboe JT (2025) Osteoporosis: A Review. JAMA 334(10):894\u2013907. https:\/\/doi.org\/10.1001\/jama.2025.6003","journal-title":"JAMA"},{"key":"8236_CR11","doi-asserted-by":"publisher","unstructured":"Camacho PM, Petak SM, Binkley N et al (2020) American Association of Clinical Endocrinologists\/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis\u20142020 Update. Endocr Pract 26:1\u201346. https:\/\/doi.org\/10.4158\/GL-2020-0524SUPPL","DOI":"10.4158\/GL-2020-0524SUPPL"},{"key":"8236_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2025.100694","volume":"53","author":"P Hadji","year":"2025","unstructured":"Hadji P, Aapro M, Al-Dagri N et al (2025) Management of aromatase inhibitor-associated bone loss (AIBL) in women with hormone-sensitive breast cancer: An updated joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG. J Bone Oncol 53: 100694. https:\/\/doi.org\/10.1016\/j.jbo.2025.100694","journal-title":"J Bone Oncol"},{"issue":"5","key":"8236_CR13","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1210\/jc.2019-00192","volume":"104","author":"P Barrionuevo","year":"2019","unstructured":"Barrionuevo P, Kapoor E, Asi N et al (2019) Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: A network meta-analysis. J Clin Endocrinol Metab 104(5):1623\u20131630. https:\/\/doi.org\/10.1210\/jc.2019-00192","journal-title":"J Clin Endocrinol Metab"},{"key":"8236_CR14","doi-asserted-by":"publisher","first-page":"e068033","DOI":"10.1136\/bmj-2021-068033","volume":"381","author":"MN H\u00e4ndel","year":"2023","unstructured":"H\u00e4ndel MN, Cardoso I, von B\u00fclow C et al (2023) Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials. BMJ 381:e068033. https:\/\/doi.org\/10.1136\/bmj-2021-068033","journal-title":"BMJ"},{"issue":"2","key":"8236_CR15","doi-asserted-by":"publisher","first-page":"182","DOI":"10.7326\/M22-0684","volume":"176","author":"C Ayers","year":"2023","unstructured":"Ayers C, Kansagara D, Lazur B, Fu R, Kwon A, Harrod C (2023) Effectiveness and safety of treatments to prevent fractures in people with low bone mass or primary Osteoporosis: A living systematic review and network meta-analysis for the American College of Physicians. Ann Intern Med 176(2):182\u2013195. https:\/\/doi.org\/10.7326\/M22-0684","journal-title":"Ann Intern Med"},{"key":"8236_CR16","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.3390\/biomedicines12081635","volume":"12","author":"NR Elahmer","year":"2024","unstructured":"Elahmer NR, Wong SK, Mohamed N, Alias E, Chin KY, Muhammad N (2024) Mechanistic insights and therapeutic strategies in osteoporosis: a comprehensive review. Biomedicines 12:1635. https:\/\/doi.org\/10.3390\/biomedicines12081635","journal-title":"Biomedicines"},{"issue":"5","key":"8236_CR17","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","volume":"104","author":"R Eastell","year":"2019","unstructured":"Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D (2019) Pharmacological management of Osteoporosis in postmenopausal women: An Endocrine Society* clinical practice guideline. J Clin Endocrinol Metab 104(5):1595\u20131622. https:\/\/doi.org\/10.1210\/jc.2019-00221","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"8236_CR18","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s00198-018-4507-8","volume":"29","author":"Y Liu","year":"2018","unstructured":"Liu Y, Levack AE, Marty E et al (2018) Anabolic agents: what is beyond osteoporosis?. Osteoporos Int 29(5):1009\u20131022. https:\/\/doi.org\/10.1007\/s00198-018-4507-8","journal-title":"Osteoporos Int"},{"key":"8236_CR19","doi-asserted-by":"publisher","first-page":"787","DOI":"10.3390\/jcm10040787","volume":"10","author":"M Rauner","year":"2021","unstructured":"Rauner M, Taipaleenm\u00e4ki H, Tsourdi E, Winter EM (2021) Osteoporosis treatment with anti-sclerostin antibodies: mechanisms of action and clinical application. J Clin Med 10:787. https:\/\/doi.org\/10.3390\/jcm10040787","journal-title":"J Clin Med"},{"issue":"2","key":"8236_CR20","doi-asserted-by":"publisher","first-page":"224","DOI":"10.7326\/M22-1034","volume":"176","author":"A Qaseem","year":"2023","unstructured":"Qaseem A, Hicks LA, Etxeandia-Ikobaltzeta I et al (2023) Pharmacologic treatment of primary Osteoporosis or low bone mass to prevent fractures in adults: A living clinical guideline From the American College of Physicians. Ann Intern Med 176(2):224\u2013238. https:\/\/doi.org\/10.7326\/M22-1034","journal-title":"Ann Intern Med"},{"key":"8236_CR21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.bonr.2018.06.007","volume":"9","author":"KB Farrell","year":"2018","unstructured":"Farrell KB, Karpeisky A, Thamm DH, Zinnen S (2018) Bisphosphonate conjugation for bone specific drug targeting. Bone Rep 9:47\u201360. https:\/\/doi.org\/10.1016\/j.bonr.2018.06.007","journal-title":"Bone Rep"},{"key":"8236_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.938447","volume":"13","author":"J Lu","year":"2022","unstructured":"Lu J, Hu D, Ma C, Shuai B (2022) Advances in our understanding of the mechanism of action of drugs (including traditional Chinese medicines) for the intervention and treatment of osteoporosis. Front Pharm 13: 938447. https:\/\/doi.org\/10.3389\/fphar.2022.938447","journal-title":"Front Pharm"},{"key":"8236_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.116289","volume":"156","author":"FH Ebetino","year":"2022","unstructured":"Ebetino FH, Hogan AM, Sun S et al (2022) Bisphosphonates: the role of chemistry in understanding their biological actions and structure-activity relationships, and new directions for their therapeutic use. Bone 156: 116289. https:\/\/doi.org\/10.1016\/j.bone.2021.116289","journal-title":"Bone"},{"issue":"1","key":"8236_CR24","doi-asserted-by":"publisher","first-page":"ITC1","DOI":"10.7326\/AITC202401160","volume":"177","author":"KE Ensrud","year":"2024","unstructured":"Ensrud KE, Crandall CJ (2024) Osteoporosis. Ann Intern Med 177(1):ITC1\u2013ITC16. https:\/\/doi.org\/10.7326\/AITC202401160","journal-title":"Ann Intern Med"},{"key":"8236_CR25","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/s0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535\u20131541. https:\/\/doi.org\/10.1016\/s0140-6736(96)07088-2","journal-title":"Lancet"},{"key":"8236_CR26","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 282:1344\u20131352. https:\/\/doi.org\/10.1001\/jama.282.14.1344","journal-title":"JAMA"},{"key":"8236_CR27","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"J Reginster","year":"2000","unstructured":"Reginster J, Minne HW, Sorensen OH et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:83\u201391. https:\/\/doi.org\/10.1007\/s001980050010","journal-title":"Osteoporos Int"},{"key":"8236_CR28","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1359\/JBMR.040325","volume":"19","author":"CH Chesnut","year":"2004","unstructured":"Chesnut CH, Skag A, Christiansen C et al (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Min Res 19:1241\u20131249. https:\/\/doi.org\/10.1359\/JBMR.040325","journal-title":"J Bone Min Res"},{"key":"8236_CR29","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809\u20131822. https:\/\/doi.org\/10.1056\/NEJMoa067312","journal-title":"N Engl J Med"},{"issue":"24","key":"8236_CR30","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"SR Cummings","year":"1998","unstructured":"Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280(24):2077\u20132082. https:\/\/doi.org\/10.1001\/jama.280.24.2077","journal-title":"JAMA"},{"key":"8236_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00198-019-05176-3","volume":"31","author":"JA Kanis","year":"2020","unstructured":"Kanis JA, Harvey NC, McCloskey E et al (2020) Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int 31:1\u201312. https:\/\/doi.org\/10.1007\/s00198-019-05176-3","journal-title":"Osteoporos Int"},{"issue":"1","key":"8236_CR32","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s12325-021-01936-y","volume":"39","author":"DL Kendler","year":"2022","unstructured":"Kendler DL, Cosman F, Stad RK, Ferrari S (2022) Denosumab in the treatment of osteoporosis: 10 years later: a narrative review. Adv Ther 39(1):58\u201374. https:\/\/doi.org\/10.1007\/s12325-021-01936-y","journal-title":"Adv Ther"},{"issue":"5","key":"8236_CR33","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41584-023-00935-3","volume":"19","author":"S Ferrari","year":"2023","unstructured":"Ferrari S, Langdahl B (2023) Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone. Nat Rev Rheumatol 19(5):307\u2013317. https:\/\/doi.org\/10.1038\/s41584-023-00935-3","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"8236_CR34","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756\u2013765. https:\/\/doi.org\/10.1056\/NEJMoa0809493","journal-title":"N Engl J Med"},{"issue":"7","key":"8236_CR35","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diab Endocrinol 5(7):513\u2013523. https:\/\/doi.org\/10.1016\/S2213-8587(17)30138-9","journal-title":"Lancet Diab Endocrinol"},{"issue":"9","key":"8236_CR36","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1093\/jbmr\/zjaf037","volume":"40","author":"S Kumar","year":"2025","unstructured":"Kumar S, Wang M, Kim AS, Center JR, McDonald MM, Girgis CM (2025) Denosumab discontinuation in the clinic: implications of rebound bone turnover and emerging strategies to prevent bone loss and fractures. J Bone Min Res 40(9):1017\u20131034. https:\/\/doi.org\/10.1093\/jbmr\/zjaf037","journal-title":"J Bone Min Res"},{"issue":"3","key":"8236_CR37","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1093\/jbmr\/zjae170","volume":"40","author":"M Schini","year":"2025","unstructured":"Schini M, Gossiel F, Saini T et al (2025) The effects of denosumab on osteoclast precursors in postmenopausal women: a possible explanation for the overshoot phenomenon after discontinuation. J Bone Min Res 40(3):301\u2013306. https:\/\/doi.org\/10.1093\/jbmr\/zjae170","journal-title":"J Bone Min Res"},{"issue":"10514","key":"8236_CR38","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1016\/S0140-6736(25)01385-6","volume":"406","author":"C Ye","year":"2025","unstructured":"Ye C, Ebeling P, Kline G (2025) Osteoporosis. Lancet 406(10514):2003\u20132016. https:\/\/doi.org\/10.1016\/S0140-6736(25)01385-6","journal-title":"Lancet"},{"issue":"21","key":"8236_CR39","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1056\/NEJMcp2307353","volume":"389","author":"MD Walker","year":"2023","unstructured":"Walker MD, Shane E (2023) Postmenopausal Osteoporosis. N Engl J Med 389(21):1979\u20131991. https:\/\/doi.org\/10.1056\/NEJMcp2307353","journal-title":"N Engl J Med"},{"issue":"7","key":"8236_CR40","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1001\/jama.282.7.637","volume":"282","author":"B Ettinger","year":"1999","unstructured":"Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282(7):637\u2013645. https:\/\/doi.org\/10.1001\/jama.282.7.637","journal-title":"JAMA"},{"issue":"12","key":"8236_CR41","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1359\/jbmr.080710","volume":"23","author":"SL Silverman","year":"2008","unstructured":"Silverman SL, Christiansen C, Genant HK et al (2008) Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Min Res 23(12):1923\u20131934. https:\/\/doi.org\/10.1359\/jbmr.080710","journal-title":"J Bone Min Res"},{"issue":"1","key":"8236_CR42","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/20533691221139902","volume":"29","author":"J Stevenson","year":"2023","unstructured":"Stevenson J (2023) Prevention and treatment of osteoporosis in women. Post Reprod Health 29(1):11\u201314. https:\/\/doi.org\/10.1177\/20533691221139902 medical advisory council of the British Menopause Society","journal-title":"Post Reprod Health"},{"issue":"6","key":"8236_CR43","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s00404-022-06647-5","volume":"307","author":"M\u0160 Gold\u0161tajn","year":"2023","unstructured":"Gold\u0161tajn M\u0160, Miku\u0161 M, Ferrari FA et al (2023) Effects of transdermal versus oral hormone replacement therapy in postmenopause: a systematic review. Arch Gynecol Obstet 307(6):1727\u20131745. https:\/\/doi.org\/10.1007\/s00404-022-06647-5","journal-title":"Arch Gynecol Obstet"},{"key":"8236_CR44","unstructured":"U.S. Food and Drug Administration (2025) FDA requests labeling changes related to safety information to clarify the benefit\/risk considerations for menopausal hormone therapies. FDA. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-requests-labeling-changes-related-safety-information-clarify-benefitrisk-considerations. Accessed 22 June 2026"},{"issue":"Suppl 1","key":"8236_CR45","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s43465-023-01034-x","volume":"57","author":"A Ghani","year":"2023","unstructured":"Ghani A, Arfee S (2023) Role of calcitonin and strontium ranelate in osteoporosis. Indian J Orthop 57(Suppl 1):115\u2013119. https:\/\/doi.org\/10.1007\/s43465-023-01034-x","journal-title":"Indian J Orthop"},{"key":"8236_CR46","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","volume":"33","author":"M LeBoff","year":"2022","unstructured":"LeBoff M, Greenspan S, Insogna K et al (2022) The clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int 33:2049\u20132102. https:\/\/doi.org\/10.1007\/s00198-021-05900-y","journal-title":"Osteoporos Int"},{"key":"8236_CR47","doi-asserted-by":"publisher","first-page":"i5109","DOI":"10.1136\/bmj.i5109","volume":"354","author":"MJ Bolland","year":"2016","unstructured":"Bolland MJ, Grey A (2016) Ten years too long: strontium ranelate, cardiac events, and the European Medicines Agency. BMJ 354:i5109. https:\/\/doi.org\/10.1136\/bmj.i5109","journal-title":"BMJ"},{"key":"8236_CR48","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3389\/fphar.2017.00265","volume":"8","author":"J Erviti","year":"2017","unstructured":"Erviti J, Gorricho J, Saiz LC, Perry T, Wright JM (2017) Rethinking the appraisal and approval of drugs for fracture prevention. Front Pharm 8:265. https:\/\/doi.org\/10.3389\/fphar.2017.00265","journal-title":"Front Pharm"},{"issue":"10","key":"8236_CR49","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41584-025-01287-w","volume":"21","author":"N Fuggle","year":"2025","unstructured":"Fuggle N, Rizzoli R, Beaudart C et al (2025) Parathyroid hormone receptor agonists in the management of osteoporosis. Nat Rev Rheumatol 21(10):599\u2013611. https:\/\/doi.org\/10.1038\/s41584-025-01287-w","journal-title":"Nat Rev Rheumatol"},{"key":"8236_CR50","doi-asserted-by":"publisher","unstructured":"Ferrari S, Thouverey C, Gerbaix M (2026) Mechanisms Underlying the Waning of Osteoanabolic Therapy Effects in Osteoporosis. J Bone Miner Res. https:\/\/doi.org\/10.1093\/jbmr\/zjag053","DOI":"10.1093\/jbmr\/zjag053"},{"issue":"2","key":"8236_CR51","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2217\/17455057.3.2.243","volume":"3","author":"JP Bilezikian","year":"2007","unstructured":"Bilezikian JP (2007) Anabolic therapy for osteoporosis. Women\u2019s Health (Lond) 3(2):243\u2013253. https:\/\/doi.org\/10.2217\/17455057.3.2.243","journal-title":"Women\u2019s Health (Lond)"},{"issue":"6","key":"8236_CR52","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.3892\/etm.2021.10815","volume":"22","author":"B Kim","year":"2021","unstructured":"Kim B, Cho YJ, Lim W (2021) Osteoporosis therapies and their mechanisms of action (review). Exp Ther Med 22(6):1379. https:\/\/doi.org\/10.3892\/etm.2021.10815","journal-title":"Exp Ther Med"},{"issue":"3","key":"8236_CR53","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00198-020-05806-1","volume":"32","author":"R Winzenrieth","year":"2021","unstructured":"Winzenrieth R, Ominsky MS, Wang Y, Humbert L, Weiss RJ (2021) Differential effects of abaloparatide and teriparatide on hip cortical volumetric BMD by DXA-based 3D modeling. Osteoporos Int 32(3):575\u2013583. https:\/\/doi.org\/10.1007\/s00198-020-05806-1","journal-title":"Osteoporos Int"},{"issue":"6","key":"8236_CR54","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1038\/s41401-022-01032-z","volume":"44","author":"LH Zhao","year":"2023","unstructured":"Zhao LH, Yuan QN, Dai AT et al (2023) Molecular recognition of two endogenous hormones by the human parathyroid hormone receptor-1. Acta Pharm Sin 44(6):1227\u20131237. https:\/\/doi.org\/10.1038\/s41401-022-01032-z","journal-title":"Acta Pharm Sin"},{"key":"8236_CR55","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434\u20131441. https:\/\/doi.org\/10.1056\/NEJM200105103441904","journal-title":"N Engl J Med"},{"key":"8236_CR56","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1210\/jc.2004-0826","volume":"90","author":"JC Gallagher","year":"2005","unstructured":"Gallagher JC, Genant HK, Crans GG, Vargas SJ, Krege JH (2005) Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. J Clin Endocrinol Metab 90:1583\u20131587. https:\/\/doi.org\/10.1210\/jc.2004-0826","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"8236_CR57","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1007\/s00223-009-9299-6","volume":"85","author":"BL Langdahl","year":"2009","unstructured":"Langdahl BL, Rajzbaum G, Jakob F et al (2009) Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS). Calcif Tissue Int 85(6):484\u2013493. https:\/\/doi.org\/10.1007\/s00223-009-9299-6","journal-title":"Calcif Tissue Int"},{"issue":"10117","key":"8236_CR58","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","volume":"391","author":"DL Kendler","year":"2018","unstructured":"Kendler DL, Marin F, Zerbini CAF et al (2018) Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 391(10117):230\u2013240. https:\/\/doi.org\/10.1016\/S0140-6736(17)32137-2","journal-title":"Lancet"},{"issue":"20","key":"8236_CR59","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1056\/NEJMoa071408","volume":"357","author":"KG Saag","year":"2007","unstructured":"Saag KG, Shane E, Boonen S et al (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357(20):2028\u20132039. https:\/\/doi.org\/10.1056\/NEJMoa071408","journal-title":"N Engl J Med"},{"key":"8236_CR60","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.2147\/CIA.S227611","volume":"15","author":"JC Thompson","year":"2020","unstructured":"Thompson JC, Wanderman N, Anderson PA, Freedman BA (2020) Abaloparatide and the spine: a narrative review. Clin Inter Aging 15:1023\u20131033. https:\/\/doi.org\/10.2147\/CIA.S227611","journal-title":"Clin Inter Aging"},{"issue":"7","key":"8236_CR61","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2016.11136","volume":"316","author":"PD Miller","year":"2016","unstructured":"Miller PD, Hattersley G, Riis BJ et al (2016) Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 316(7):722\u2013733. https:\/\/doi.org\/10.1001\/jama.2016.11136","journal-title":"JAMA"},{"key":"8236_CR62","unstructured":"U.S. Food and Drug Administration (2017) NDA 208743 approval letter: TYMLOS (abaloparatide) injection. Center for Drug Evaluation and Research. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2017\/208743Orig1s000ltr.pdf. Accessed 22 June 2026"},{"key":"8236_CR63","unstructured":"European Medicines Agency (2018) Questions and answers on the refusal of the marketing authorisation for Eladynos (abaloparatide): outcome of re-examination. EMA\/504599\/2018. https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_en.pdf. Accessed 22 July 2026"},{"key":"8236_CR64","unstructured":"European Medicines Agency (2018) Eladynos (abaloparatide): EPAR \u2013 refusal public assessment report. EMA\/CHMP\/581111\/2018. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/eladynos-epar-refusal-public-assessment-report_en.pdf. Accessed 22 June 2026"},{"issue":"8","key":"8236_CR65","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1007\/s00198-022-06413-y","volume":"33","author":"F Cosman","year":"2022","unstructured":"Cosman F, Cooper C, Wang Y, Mitlak B, Varughese S, Williams SA (2022) Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: A US administrative claims database study. Osteoporos Int 33(8):1703\u20131714. https:\/\/doi.org\/10.1007\/s00198-022-06413-y","journal-title":"Osteoporos Int"},{"issue":"10","key":"8236_CR66","doi-asserted-by":"publisher","first-page":"e4222","DOI":"10.1210\/clinem\/dgac486","volume":"107","author":"T Matsumoto","year":"2022","unstructured":"Matsumoto T, Sone T, Soen S, Tanaka S, Yamashita A, Inoue T (2022) Abaloparatide Increases Lumbar Spine and Hip BMD in Japanese Patients With Osteoporosis: The Phase 3 ACTIVE-J Study. J Clin Endocrinol Metab 107(10):e4222\u2013e4231. https:\/\/doi.org\/10.1210\/clinem\/dgac486","journal-title":"J Clin Endocrinol Metab"},{"key":"8236_CR67","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.bone.2016.11.004","volume":"97","author":"CA Moreira","year":"2017","unstructured":"Moreira CA, Fitzpatrick LA, Wang Y, Recker RR (2017) Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: The ACTIVE phase 3 trial. Bone 97:314\u2013319. https:\/\/doi.org\/10.1016\/j.bone.2016.11.004","journal-title":"Bone"},{"key":"#cr-split#-8236_CR68.1","unstructured":"European Commission (2022) Commission implementing decision of 12.12.2022 granting marketing authorisation under Regulation"},{"key":"#cr-split#-8236_CR68.2","unstructured":"(EC) No 726\/2004 for \"Eladynos - abaloparatide\", a medicinal product for human use. C(2022) 9555 final. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2022\/20221212157506\/dec_157506_en.pdf. Accessed 22 June 2026"},{"issue":"5","key":"8236_CR69","doi-asserted-by":"publisher","first-page":"707","DOI":"10.20945\/2359-3997000000566","volume":"66","author":"L Bandeira","year":"2022","unstructured":"Bandeira L, Lewiecki EM (2022) Anabolic therapy for osteoporosis: update on efficacy and safety. Arch Endocrinol Metab 66(5):707\u2013716. https:\/\/doi.org\/10.20945\/2359-3997000000566","journal-title":"Arch Endocrinol Metab"},{"issue":"9","key":"8236_CR70","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3949\/ccjm.88a.21011","volume":"88","author":"PD Miller","year":"2021","unstructured":"Miller PD, Lewiecki EM, Krohn K, Schwartz E (2021) Teriparatide: Label changes and identifying patients for long-term use. Cleve Clin J Med 88(9):489\u2013493. https:\/\/doi.org\/10.3949\/ccjm.88a.21011","journal-title":"Cleve Clin J Med"},{"issue":"3","key":"8236_CR71","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1080\/01926230252929882","volume":"30","author":"JL Vahle","year":"2002","unstructured":"Vahle JL, Sato M, Long GG et al (2002) Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 30(3):312\u2013321. https:\/\/doi.org\/10.1080\/01926230252929882","journal-title":"Toxicol Pathol"},{"issue":"9","key":"8236_CR72","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10665","volume":"6","author":"JH Krege","year":"2022","unstructured":"Krege JH, Gilsenan AW, Komacko JL, Kellier-Steele N (2022) Teriparatide and osteosarcoma risk: History, science, elimination of boxed warning, and other label updates. JBMR 6(9):e10665. https:\/\/doi.org\/10.1002\/jbm4.10665","journal-title":"JBMR"},{"issue":"4","key":"8236_CR73","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1359\/jbmr.081215","volume":"24","author":"R Eastell","year":"2009","unstructured":"Eastell R, Nickelsen T, Marin F et al (2009) Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). J Bone Min Res 24(4):726\u2013736. https:\/\/doi.org\/10.1359\/jbmr.081215","journal-title":"J Bone Min Res"},{"issue":"6","key":"8236_CR74","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1056\/NEJMoa050336","volume":"353","author":"DM Black","year":"2005","unstructured":"Black DM, Bilezikian JP, Ensrud KE et al (2005) One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 353(6):555\u2013565. https:\/\/doi.org\/10.1056\/NEJMoa050336","journal-title":"N Engl J Med"},{"issue":"16","key":"8236_CR75","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375(16):1532\u20131543. https:\/\/doi.org\/10.1056\/NEJMoa1607948","journal-title":"N Engl J Med"},{"issue":"15","key":"8236_CR76","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML et al (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377(15):1417\u20131427. https:\/\/doi.org\/10.1056\/NEJMoa1708322","journal-title":"N Engl J Med"},{"issue":"5","key":"8236_CR77","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S et al (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370(5):412\u2013420. https:\/\/doi.org\/10.1056\/NEJMoa1305224","journal-title":"N Engl J Med"},{"issue":"10102","key":"8236_CR78","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","volume":"390","author":"BL Langdahl","year":"2017","unstructured":"Langdahl BL, Libanati C, Crittenden DB et al (2017) Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet 390(10102):1585\u20131594. https:\/\/doi.org\/10.1016\/S0140-6736(17)31613-6","journal-title":"Lancet"},{"issue":"1","key":"8236_CR79","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1177\/8755122520967632","volume":"37","author":"SA Miller","year":"2021","unstructured":"Miller SA, St Onge EL, Whalen KL (2021) Romosozumab: a novel agent in the treatment for postmenopausal osteoporosis. J Pharm Technol 37(1):45\u201352. https:\/\/doi.org\/10.1177\/8755122520967632","journal-title":"J Pharm Technol"},{"key":"8236_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2022.101635","volume":"17","author":"H Inose","year":"2022","unstructured":"Inose H, Kato T, Tomizawa S et al (2022) Impact of romosozumab on serum calcium concentration and factors predicting the fluctuations in calcium concentration upon romosozumab administration: a multicenter retrospective study. Bone Rep 17: 101635. https:\/\/doi.org\/10.1016\/j.bonr.2022.101635","journal-title":"Bone Rep"},{"key":"8236_CR81","doi-asserted-by":"publisher","DOI":"10.1177\/17455057221125577","volume":"18","author":"SY Lim","year":"2022","unstructured":"Lim SY (2022) Romosozumab for the treatment of osteoporosis in women: Efficacy, safety, and cardiovascular risk. Women\u2019s Health (Lond) 18: 17455057221125577. https:\/\/doi.org\/10.1177\/17455057221125577","journal-title":"Women\u2019s Health (Lond)"},{"key":"8236_CR82","unstructured":"European Medicines Agency (2020) Evenity (romosozumab): EPAR \u2013 public assessment report. EMA\/26554\/2020. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/evenity-epar-public-assessment-report_en.pdf. Accessed 22 June 2026"},{"issue":"12","key":"8236_CR83","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1080\/17460441.2025.2594642","volume":"20","author":"P Geusens","year":"2025","unstructured":"Geusens P, Van Hul W, van den Bergh J, Lems W (2025) The preclinical discovery and development of romosozumab for the treatment of people with severe osteoporosis who are at high risk of fracture. Expert Opin Drug Discov 20(12):1475\u20131492. https:\/\/doi.org\/10.1080\/17460441.2025.2594642","journal-title":"Expert Opin Drug Discov"},{"key":"8236_CR84","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jot.2024.07.011","volume":"48","author":"RMY Wong","year":"2024","unstructured":"Wong RMY, Wong PY, Liu C et al (2024) Treatment effects, adverse outcomes and cardiovascular safety of romosozumab - existing worldwide data: a systematic review and meta-analysis. J Orthop Transl 48:107\u2013122. https:\/\/doi.org\/10.1016\/j.jot.2024.07.011","journal-title":"J Orthop Transl"},{"key":"8236_CR85","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1007\/s10067-020-04948-1","volume":"39","author":"S Kaveh","year":"2020","unstructured":"Kaveh S, Hosseinifard H, Ghadimi N et al (2020) Efficacy and safety of romosozumab in treatment for low bone mineral density: a systematic review and meta-analysis. Clin Rheumatol 39:3261\u20133276. https:\/\/doi.org\/10.1007\/s10067-020-04948-1","journal-title":"Clin Rheumatol"},{"issue":"1","key":"8236_CR86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00198-021-06095-y","volume":"33","author":"S Singh","year":"2022","unstructured":"Singh S, Dutta S, Khasbage S et al (2022) A systematic review and meta-analysis of efficacy and safety of romosozumab in postmenopausal osteoporosis. Osteoporos Int 33(1):1\u201312. https:\/\/doi.org\/10.1007\/s00198-021-06095-y","journal-title":"Osteoporos Int"},{"issue":"3","key":"8236_CR87","doi-asserted-by":"publisher","first-page":"e861","DOI":"10.1210\/clinem\/dgae173","volume":"110","author":"J Stokar","year":"2025","unstructured":"Stokar J, Szalat A (2025) Cardiovascular safety of romosozumab vs PTH analogues for osteoporosis treatment: A propensity-score-matched cohort study. J Clin Endocrinol Metab 110(3):e861\u2013e867. https:\/\/doi.org\/10.1210\/clinem\/dgae173","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"8236_CR88","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1002\/cpt.70142","volume":"119","author":"H Maruyama","year":"2026","unstructured":"Maruyama H, Iwasa E, Watanabe S, Hasegawa T, Kajiyama K, Tanaka T (2026) Cardiovascular risk of romosozumab vs. teriparatide: A cohort study using Japan\u2019s national claims database. Clin Pharm Ther 119(3):721\u2013728. https:\/\/doi.org\/10.1002\/cpt.70142","journal-title":"Clin Pharm Ther"},{"issue":"1","key":"8236_CR89","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/14712598.2022.2152320","volume":"23","author":"P Geusens","year":"2023","unstructured":"Geusens P, Appelman-Dijkstra N, Lems W, van den Bergh J (2023) Romosozumab for the treatment of postmenopausal women at high risk of fracture. Expert Opin Biol Ther 23(1):11\u201319. https:\/\/doi.org\/10.1080\/14712598.2022.2152320","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"8236_CR90","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s12020-019-01919-8","volume":"64","author":"N Gua\u00f1abens","year":"2019","unstructured":"Gua\u00f1abens N, Moro-\u00c1lvarez MJ, Casado E et al (2019) The next step after anti-osteoporotic drug discontinuation: an up-to-date review of sequential treatment. Endocrine 64(3):441\u2013455. https:\/\/doi.org\/10.1007\/s12020-019-01919-8","journal-title":"Endocrine"},{"key":"8236_CR91","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00198-018-4790-4","volume":"30","author":"S Lou","year":"2019","unstructured":"Lou S, Lv H, Yin P, Li Z, Tang P, Wang Y (2019) Combination therapy with parathyroid hormone analogs and antiresorptive agents for osteoporosis: a systematic review and meta-analysis of randomized controlled trials. Osteoporos Int 30:59\u201370. https:\/\/doi.org\/10.1007\/s00198-018-4790-4","journal-title":"Osteoporos Int"},{"issue":"9","key":"8236_CR92","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1111\/bph.15024","volume":"178","author":"BL Langdahl","year":"2021","unstructured":"Langdahl BL (2021) Overview of treatment approaches to osteoporosis. Br J Pharm 178(9):1891\u20131906. https:\/\/doi.org\/10.1111\/bph.15024","journal-title":"Br J Pharm"},{"issue":"2","key":"8236_CR93","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1210\/clinem\/dgad496","volume":"109","author":"SK Ramchand","year":"2024","unstructured":"Ramchand SK, Leder BZ (2024) Sequential therapy for the long-term treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 109(2):303\u2013311. https:\/\/doi.org\/10.1210\/clinem\/dgad496","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"8236_CR94","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.eprac.2024.01.014","volume":"30","author":"F Cosman","year":"2024","unstructured":"Cosman F, Langdahl B, Leder BZ (2024) Treatment sequence for osteoporosis. Endocr Pract 30(5):490\u2013496. https:\/\/doi.org\/10.1016\/j.eprac.2024.01.014","journal-title":"Endocr Pract"},{"issue":"18","key":"8236_CR95","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1001\/archinte.164.18.2024","volume":"164","author":"R Lindsay","year":"2004","unstructured":"Lindsay R, Scheele WH, Neer R et al (2004) Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 164(18):2024\u20132030. https:\/\/doi.org\/10.1001\/archinte.164.18.2024","journal-title":"Arch Intern Med"},{"issue":"7","key":"8236_CR96","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1002\/jbmr.3427","volume":"33","author":"F Cosman","year":"2018","unstructured":"Cosman F, Crittenden DB, Ferrari S et al (2018) FRAME study: the foundation effect of building bone with 1 year of romosozumab leads to continued lower fracture risk after transition to denosumab. J Bone Min Res 33(7):1219\u20131226. https:\/\/doi.org\/10.1002\/jbmr.3427","journal-title":"J Bone Min Res"},{"issue":"9999","key":"8236_CR97","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","volume":"386","author":"BZ Leder","year":"2015","unstructured":"Leder BZ, Tsai JN, Uihlein AV et al (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 386(9999):1147\u20131155. https:\/\/doi.org\/10.1016\/S0140-6736(15)61120-5","journal-title":"Lancet"},{"issue":"8","key":"8236_CR98","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1210\/jc.2018-00163","volume":"103","author":"HG Bone","year":"2018","unstructured":"Bone HG, Cosman F, Miller PD et al (2018) ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis. J Clin Endocrinol Metab 103(8):2949\u20132957. https:\/\/doi.org\/10.1210\/jc.2018-00163","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"8236_CR99","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1359\/jbmr.081250","volume":"24","author":"F Cosman","year":"2009","unstructured":"Cosman F, Nieves JW, Zion M, Barbuto N, Lindsay R (2009) Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate. J Bone Min Res 24(6):1110\u20131115. https:\/\/doi.org\/10.1359\/jbmr.081250","journal-title":"J Bone Min Res"},{"issue":"7","key":"8236_CR100","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1210\/jc.2009-0154","volume":"94","author":"JS Finkelstein","year":"2009","unstructured":"Finkelstein JS, Wyland JJ, Leder BZ et al (2009) Effects of teriparatide retreatment in osteoporotic men and women. J Clin Endocrinol Metab 94(7):2495\u20132501. https:\/\/doi.org\/10.1210\/jc.2009-0154","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"8236_CR101","doi-asserted-by":"publisher","DOI":"10.1093\/jbmrpl\/ziae131","volume":"8","author":"T Kobayakawa","year":"2024","unstructured":"Kobayakawa T, Kanayama Y, Hirano Y, Yukishima T, Nakamura Y (2024) Therapy with transitions from one bone-forming agent to another: a retrospective cohort study on teriparatide and romosozumab. JBMR 8(12):ziae131. https:\/\/doi.org\/10.1093\/jbmrpl\/ziae131","journal-title":"JBMR"},{"issue":"2","key":"8236_CR102","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/jbmr.3051","volume":"32","author":"F Cosman","year":"2017","unstructured":"Cosman F, Nieves JW, Dempster DW (2017) Treatment sequence matters: Anabolic and antiresorptive therapy for osteoporosis. J Bone Min Res 32(2):198\u2013202. https:\/\/doi.org\/10.1002\/jbmr.3051","journal-title":"J Bone Min Res"},{"issue":"10","key":"8236_CR103","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1359\/jbmr.080506","volume":"23","author":"BM Obermayer-Pietsch","year":"2008","unstructured":"Obermayer-Pietsch BM, Marin F, McCloskey EV et al. (2008) Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Min Res 23(10):1591\u20131600. https:\/\/doi.org\/10.1359\/jbmr.080506","journal-title":"J Bone Min Res"},{"issue":"10","key":"8236_CR104","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1210\/jc.2008-0353","volume":"93","author":"PD Miller","year":"2008","unstructured":"Miller PD, Delmas PD, Lindsay R et al (2008) Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab 93(10):3785\u20133793. https:\/\/doi.org\/10.1210\/jc.2008-0353","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"8236_CR105","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1210\/jc.2008-2719","volume":"94","author":"F Cosman","year":"2009","unstructured":"Cosman F, Wermers RA, Recknor C et al (2009) Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J Clin Endocrinol Metab 94(10):3772\u20133780. https:\/\/doi.org\/10.1210\/jc.2008-2719","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"8236_CR106","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10512","volume":"5","author":"MR McClung","year":"2021","unstructured":"McClung MR, Bolognese MA, Brown JP et al (2021) Skeletal responses to romosozumab after 12 months of denosumab. JBMR 5(7):e10512. https:\/\/doi.org\/10.1002\/jbm4.10512","journal-title":"JBMR"},{"issue":"9","key":"8236_CR107","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1007\/s00198-024-07155-9","volume":"35","author":"J Everts-Graber","year":"2024","unstructured":"Everts-Graber J, Wenger M, Oser S et al (2024) The effect of romosozumab on bone mineral density depending on prior treatment: a prospective, multicentre cohort study in Switzerland. Osteoporos Int 35(9):1605\u20131613. https:\/\/doi.org\/10.1007\/s00198-024-07155-9","journal-title":"Osteoporos Int"},{"issue":"5","key":"8236_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2021.105219","volume":"88","author":"K Ebina","year":"2021","unstructured":"Ebina K, Tsuboi H, Nagayama Y et al (2021) Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis. Jt Bone Spine 88(5):105219. https:\/\/doi.org\/10.1016\/j.jbspin.2021.105219","journal-title":"Jt Bone Spine"},{"key":"8236_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2021.101068","volume":"14","author":"T Kobayakawa","year":"2021","unstructured":"Kobayakawa T, Suzuki T, Nakano M et al (2021) Real-world effects and adverse events of romosozumab in Japanese osteoporotic patients: a prospective cohort study. Bone Rep 14: 101068. https:\/\/doi.org\/10.1016\/j.bonr.2021.101068","journal-title":"Bone Rep"},{"issue":"2","key":"8236_CR110","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/jbmr\/zjae179","volume":"40","author":"N Hong","year":"2025","unstructured":"Hong N, Shin S, Kim H, Cho SJ, Park JA, Rhee Y (2025) Romosozumab following denosumab improves lumbar spine bone mineral density and trabecular bone score greater than denosumab continuation in postmenopausal women. J Bone Min Res 40(2):184\u2013192. https:\/\/doi.org\/10.1093\/jbmr\/zjae179","journal-title":"J Bone Min Res"},{"issue":"2","key":"8236_CR111","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","volume":"33","author":"SR Cummings","year":"2018","unstructured":"Cummings SR, Ferrari S, Eastell R et al (2018) Vertebral fractures after discontinuation of denosumab: A post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Min Res 33(2):190\u2013198. https:\/\/doi.org\/10.1002\/jbmr.3337","journal-title":"J Bone Min Res"},{"issue":"3","key":"8236_CR112","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s40265-024-02138-w","volume":"85","author":"N Fuggle","year":"2025","unstructured":"Fuggle N, Laslop A, Rizzoli R et al. (2025) Treatment of osteoporosis and osteoarthritis in the oldest old. Drugs 85(3):343\u2013360. https:\/\/doi.org\/10.1007\/s40265-024-02138-w","journal-title":"Drugs"},{"key":"8236_CR113","doi-asserted-by":"publisher","DOI":"10.1177\/20420188211010052","volume":"12","author":"JA Noble","year":"2021","unstructured":"Noble JA, McKenna MJ, Crowley RK (2021) Should denosumab treatment for osteoporosis be continued indefinitely?. Ther Adv Endocrinol Metab 12: 20420188211010052. https:\/\/doi.org\/10.1177\/20420188211010052","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"10","key":"8236_CR114","doi-asserted-by":"publisher","first-page":"e4155","DOI":"10.1210\/clinem\/dgab321","volume":"106","author":"P Makras","year":"2021","unstructured":"Makras P, Appelman-Dijkstra NM, Papapoulos SE et al. (2021) The duration of denosumab treatment and the efficacy of zoledronate to preserve bone mineral density after its discontinuation. J Clin Endocrinol Metab 106(10):e4155\u2013e4162. https:\/\/doi.org\/10.1210\/clinem\/dgab321","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"8236_CR115","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1002\/jbmr.3853","volume":"34","author":"AD Anastasilakis","year":"2019","unstructured":"Anastasilakis AD, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Makras P (2019) Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. A prospective 2-year clinical trial. J Bone Min Res 34(12):2220\u20132228. https:\/\/doi.org\/10.1002\/jbmr.3853","journal-title":"J Bone Min Res"},{"issue":"3","key":"8236_CR116","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00198-022-06648-9","volume":"34","author":"T Tutaworn","year":"2023","unstructured":"Tutaworn T, Nieves JW, Wang Z, Levin JE, Yoo JE, Lane JM (2023) Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study. Osteoporos Int 34(3):573\u2013584. https:\/\/doi.org\/10.1007\/s00198-022-06648-9","journal-title":"Osteoporos Int"},{"issue":"3","key":"8236_CR117","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1530\/EJE-21-0157","volume":"185","author":"G Grassi","year":"2021","unstructured":"Grassi G, Chiodini I, Palmieri S, Cairoli E, Arosio M, Eller-Vainicher C (2021) Bisphosphonates after denosumab withdrawal reduce the vertebral fractures incidence. Eur J Endocrinol 185(3):387\u2013396. https:\/\/doi.org\/10.1530\/EJE-21-0157","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"8236_CR118","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1210\/jc.2016-1801","volume":"101","author":"PD Miller","year":"2016","unstructured":"Miller PD, Pannacciulli N, Brown JP et al (2016) Denosumab or zoledronic acid in postmenopausal women with Osteoporosis previously treated with oral bisphosphonates. J Clin Endocrinol Metab 101(8):3163\u20133170. https:\/\/doi.org\/10.1210\/jc.2016-1801","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"8236_CR119","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00198-018-4790-4","volume":"30","author":"S Lou","year":"2019","unstructured":"Lou S, Lv H, Yin P, Li Z, Tang P, Wang Y (2019) Combination therapy with parathyroid hormone analogs and antiresorptive agents for osteoporosis: a systematic review and meta-analysis of randomized controlled trials. Osteoporos Int 30(1):59\u201370. https:\/\/doi.org\/10.1007\/s00198-018-4790-4","journal-title":"Osteoporos Int"},{"issue":"13","key":"8236_CR120","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa031975","volume":"349","author":"DM Black","year":"2003","unstructured":"Black DM, Greenspan SL, Ensrud KE et al (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349(13):1207\u20131215. https:\/\/doi.org\/10.1056\/NEJMoa031975","journal-title":"N Engl J Med"},{"issue":"4","key":"8236_CR121","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1210\/jc.2009-1703","volume":"95","author":"JS Finkelstein","year":"2010","unstructured":"Finkelstein JS, Wyland JJ, Lee H, Neer RM (2010) Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 95(4):1838\u20131845. https:\/\/doi.org\/10.1210\/jc.2009-1703","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"8236_CR122","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/jbmr.238","volume":"26","author":"F Cosman","year":"2011","unstructured":"Cosman F, Eriksen EF, Recknor C et al (2011) Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Min Res 26(3):503\u2013511. https:\/\/doi.org\/10.1002\/jbmr.238","journal-title":"J Bone Min Res"},{"issue":"6","key":"8236_CR123","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1056\/NEJMoa050157","volume":"353","author":"F Cosman","year":"2005","unstructured":"Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, Lindsay R (2005) Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 353(6):566\u2013575. https:\/\/doi.org\/10.1056\/NEJMoa050157","journal-title":"N Engl J Med"},{"issue":"11","key":"8236_CR124","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1359\/JBMR.050714","volume":"20","author":"C Deal","year":"2005","unstructured":"Deal C, Omizo M, Schwartz EN et al (2005) Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Min Res 20(11):1905\u20131911. https:\/\/doi.org\/10.1359\/JBMR.050714","journal-title":"J Bone Min Res"},{"issue":"9886","key":"8236_CR125","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","volume":"382","author":"JN Tsai","year":"2013","unstructured":"Tsai JN, Uihlein AV, Lee H et al (2013) Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet 382(9886):50\u201356. https:\/\/doi.org\/10.1016\/S0140-6736(13)60856-9","journal-title":"Lancet"},{"key":"8236_CR126","doi-asserted-by":"publisher","DOI":"10.1038\/boneres.2016.55","volume":"5","author":"Y Nakamura","year":"2017","unstructured":"Nakamura Y, Suzuki T, Kamimura M et al (2017) Two-year clinical outcome of denosumab treatment alone and in combination with teriparatide in Japanese treatment-naive postmenopausal osteoporotic women. Bone Res 5: 16055. https:\/\/doi.org\/10.1038\/boneres.2016.55","journal-title":"Bone Res"},{"issue":"11","key":"8236_CR127","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1007\/s00198-016-3647-y","volume":"27","author":"L Idolazzi","year":"2016","unstructured":"Idolazzi L, Rossini M, Viapiana O et al (2016) Teriparatide and denosumab combination therapy and skeletal metabolism. Osteoporos Int 27(11):3301\u20133307. https:\/\/doi.org\/10.1007\/s00198-016-3647-y","journal-title":"Osteoporos Int"},{"issue":"4","key":"8236_CR128","doi-asserted-by":"publisher","DOI":"10.1093\/jbmrpl\/ziae016","volume":"8","author":"G Adami","year":"2024","unstructured":"Adami G, Pedrollo E, Rossini M et al (2024) Romosozumab added to ongoing denosumab in postmenopausal osteoporosis, a prospective observational study. JBMR 8(4):ziae016. https:\/\/doi.org\/10.1093\/jbmrpl\/ziae016","journal-title":"JBMR"},{"issue":"4","key":"8236_CR129","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1080\/14656566.2020.1717468","volume":"21","author":"AD Anastasilakis","year":"2020","unstructured":"Anastasilakis AD, Polyzos SA, Yavropoulou MP, Makras P (2020) Combination and sequential treatment in women with postmenopausal osteoporosis. Expert Opin Pharmacother 21(4):477\u2013490. https:\/\/doi.org\/10.1080\/14656566.2020.1717468","journal-title":"Expert Opin Pharmacother"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08236-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-08236-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08236-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:02:48Z","timestamp":1790902968000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-026-08236-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":130,"alternative-id":["8236"],"URL":"https:\/\/doi.org\/10.1007\/s00198-026-08236-7","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"assertion":[{"value":"19 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors VR, CR, RB, AT, FPC, and AC declare that they have no conflict of interest.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}